Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular AVI-4658 in Duchenne Muscular Dystrophy
NCT00159250Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Oct 2007
- Primary completion
- Dec 2008
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, single-blind trial of eteplirsen in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Imperial College London. Primary endpoints: Number of Participants With Adverse Events Related to AVI-4568 at Day 120, Number of Participants With Injection Site Reactions at Day 3 and 1 more. Started Oct 2007; status: completed.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT00159250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159250.